THE rs2200733 POLYMORPHISM ON CHROMOSOME 4q25 AFFECTS THE EFFICIENCY OF PULMONALY VEIN ISOLATION IN PATIENTS IN ATRIAL FIBRILLATION

Abstract

Atrial fibrillation (AF) is one of the most common cardiac arrhythmias, accounting for 1-2% in the general population. Currently, such a method of surgical treatment of AF as catheter ablation of the orifices of the pulmonary veins (CA PVV) is widely used. In the foreign literature in recent years, the results of single studies have appeared, which showed a clear association between the rs2200733 polymorphism and the occurrence of AF relapses after CA PVV. Such studies have not been conducted on the Russian population. Purpose of the study: to determine the relationship between the rs2200733 polymorphism of chromosome 4q25 and the efficiency of CA PVV in AF. A total of 113 patients with primary AF and 134 with secondary AF were examined. Control - 182 healthy people. A subgroup of 67 people was formed, with the conducted CA PVV from patients with primary AF. Conducted: ECG, EchoCG, Holter ECG monitoring, VEM, CAG, molecular genetic research. Among patients with recurrent AF after CA PVV, the TT genotype was detected statistically significantly more often than in patients without recurrence (20.00% relative to 0.00%, p<0.05), while if there is a genotype with the T allele, the risk of AF recurrence increased 3.6 times (OR 3.636; CI 95% 1.324-9.991). The median relapse-free survival (which represents the time during which AF relapse occurs in 50% of patients) is 12.00 ± 0.66 months in the presence of the CT genotype (95% CI 10.70-13.30), 11.00 ± 2.99 months in patients with the TT genotype (95% CI 5.14-16.86). The median relapse-free survival was not determined in patients with the CС genotype, since the number of patients without signs of relapse of the disease was more than 50% by the end of the observation period. In this study, for the first time in the Russian population, it has been shown that the TT genotype and the T allele of the rs2200733 polymorphism are predictors of early recurrence of AF after CA PVV.